BIOMARIN PHARMACEUTICAL INC

Drug pipeline (7)

Asset	Stage	Revenue	Trials	Status
ELOSULFASE ALFA	approved	—	6	approved
GALSULFASE	approved	—	1	approved
LARONIDASE	approved	—	0	—
Sapropterin Dihydrochloride	approved	—	14	approved
VOSORITIDE	approved	—	12	approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (81)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT04554940	phase2	active_not_recruiting	2020-10-10	2027-12-01	BioMarin Pharmaceutical	A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia
NCT03583697	phase2	completed	2018-06-13	2022-01-26	BioMarin Pharmaceutical	A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
NCT01275066	phase3	completed	2011-02-01	2012-08-01	BioMarin Pharmaceutical	A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
NCT05121376	phase1_2	active_not_recruiting	2022-02-15	2028-11-01	BioMarin Pharmaceutical	A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
NCT00789568	phase1	completed	2008-10-01	2009-01-01	BioMarin Pharmaceutical	A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

FDA applications (9)

Application

Type

Applicant

Products

BLA 125058

BLA

BioMarin Pharmaceutical Inc.

BLA 125117

BLA

BioMarin Pharmaceutical Inc.

BLA 125460

BLA

BioMarin Pharmaceutical Inc.

BLA 125720

BLA

Biomarin Pharmaceutical Inc.

BLA 761052

BLA

BioMarin Pharmaceutical Inc.